{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T12:21:42Z","timestamp":1781094102724,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In Kazakhstan, the number of people living with HIV (PLHIV) has increased steadily by 39% since 2010. Development of antiretroviral therapy (ART) resistance mutations (ARTRM) is a major hurdle in achieving effective treatment and prevention against HIV. Using HIV <jats:italic>pol<\/jats:italic> sequences from 602 PLHIV from Kazakhstan, we analyzed ARTRMs for their association with factors that may promote development of ARTRMs. 56% PLHIV were infected with HIV subtype A6 and 42% with CRF02_AG. The ARTRM Q174K was associated with increased viral load and decreased CD4+ cell count, while infection with CRF02_AG was associated with a lower likelihood of Q174K. Interestingly, CRF02_AG was positively associated with the ARTRM L10V that, in turn, was observed frequently with darunavir administration. Infection with CRF02_AG was positively associated with the ARTRM S162A that, in turn, was frequently observed with the administration of nevirapine, also associated with lower CD4 counts. Zidovudine or Nevirapine receipt was associated with the development of the ARTRM E138A, that, in turn, was associated with lower CD4 counts. Determination of a patient\u2019s HIV variant can help guide ART choice in Kazakhstan. For example, PLHIV infected with CRF02_AG will benefit less from darunavir and nevirapine, and emtricitabine should replace zidovudine.<\/jats:p>","DOI":"10.1038\/s41598-022-22163-7","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T15:06:09Z","timestamp":1665673569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan"],"prefix":"10.1038","volume":"12","author":[{"given":"Ainur","family":"Mukhatayeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidana","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Dzissyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpamys","family":"Issanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhussipbek","family":"Mukhatayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bauyrzhan","family":"Bayserkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten H.","family":"Vermund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"22163_CR1","unstructured":"Global HIV & AIDS statistics\u20142021. 2021 [cited 2021 September]. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf."},{"key":"22163_CR2","unstructured":"Regional factsheets: Eastern Europe and Central Asia\u20142020. 2021. https:\/\/aidsinfo.unaids.org\/?did=554c9b9c05b5b281750af202&r=world&t=null&tb=q&bt=undefined&ts=0,0&qla=R&qls=UNAEECA. Accessed September 2021."},{"key":"22163_CR3","unstructured":"Country report: Kazakhstan\u20142021. UNAIDS Country report: Kazakhstan. https:\/\/www.unaids.org\/en\/regionscountries\/countries\/kazakhstan [cited 2022 March]."},{"key":"22163_CR4","unstructured":"Kemnic, T.R., G.P. HIV Antiretroviral Therapy, ed. (T.I.F.S. Publishing, 2020)."},{"key":"22163_CR5","unstructured":"Regulatory acts on HIV infection in Kazakhstan. [cited 2022 June]. https:\/\/gcaids.kz\/images\/spicokNPA.pdf."},{"key":"22163_CR6","unstructured":"Clinical protocol for diagnosis and treatment of HIV infection in adults. 2020 [cited 2021 May]. https:\/\/online.zakon.kz\/Document\/?doc_id=34669800#pos=67;-48."},{"key":"22163_CR7","unstructured":"Recommendations for the diagnosis and treatment of HIV infection in adults and children have been updated in Kazakhstan. 2020 [cited 2022 July]. https:\/\/itpc-eeca.org\/2020\/06\/17\/v-kazahstane-obnovleny-rekomendaczii-po-diagnostike-i-lecheniyu-vich-infekczii-u-vzroslyh-i-detej\/."},{"key":"22163_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","volume":"46","author":"DS Clutter","year":"2016","unstructured":"Clutter, D. S. et al. HIV-1 drug resistance and resistance testing. Infect. Genet. Evol. 46, 292\u2013307 (2016).","journal-title":"Infect. Genet. Evol."},{"key":"22163_CR9","unstructured":"90\u201390\u201390\u2014An ambitious treatment target to help end the AIDS epidemic. 2017 [cited 2020 June]. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/90-90-90_en.pdf."},{"key":"22163_CR10","unstructured":"Kazakhstan: Progress towards 90\u201390\u201390. 2021 [cited 2022 June]. https:\/\/aidsinfo.unaids.org\/?did=554c9b9c05b5b281750af202&r=world&t=null&tb=g&bt=gnli&ts=0,0&gid=5977091c3ba08432558d099c&gr=KAZ."},{"issue":"19","key":"22163_CR11","doi-asserted-by":"publisher","first-page":"9864","DOI":"10.1128\/JVI.00915-10","volume":"84","author":"ME Abram","year":"2010","unstructured":"Abram, M. E. et al. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J. Virol. 84(19), 9864\u20139878 (2010).","journal-title":"J. Virol."},{"issue":"5197","key":"22163_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1126\/science.7824947","volume":"267","author":"JM Coffin","year":"1995","unstructured":"Coffin, J. M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267(5197), 483\u2013489 (1995).","journal-title":"Science"},{"issue":"12","key":"22163_CR13","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1073\/pnas.0306764101","volume":"101","author":"DN Levy","year":"2004","unstructured":"Levy, D. N. et al. Dynamics of HIV-1 recombination in its natural target cells. Proc. Natl. Acad. Sci. USA 101(12), 4204\u20134209 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"22163_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1006\/viro.1996.0436","volume":"222","author":"LM Mansky","year":"1996","unstructured":"Mansky, L. M. The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology 222(2), 391\u2013400 (1996).","journal-title":"Virology"},{"issue":"2","key":"22163_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165110","volume":"12","author":"F Zhang","year":"2017","unstructured":"Zhang, F. et al. An analysis of drug resistance among people living with HIV\/AIDS in Shanghai, China. PLoS ONE 12(2), e0165110 (2017).","journal-title":"PLoS ONE"},{"issue":"7","key":"22163_CR16","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/tmi.12717","volume":"21","author":"J Ndahimana","year":"2016","unstructured":"Ndahimana, J. et al. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Trop. Med. Int. Health 21(7), 928\u2013935 (2016).","journal-title":"Trop. Med. Int. Health"},{"key":"22163_CR17","unstructured":"HIV drug resistance report. 2019 [cited 2021 June]. https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-HIV-19.21."},{"key":"22163_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.meegid.2013.04.032","volume":"19","author":"AC Pineda-Pena","year":"2013","unstructured":"Pineda-Pena, A. C. et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools. Infect. Genet. Evol. 19, 337\u2013348 (2013).","journal-title":"Infect. Genet. Evol."},{"issue":"11","key":"22163_CR19","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1089\/aid.1995.11.1413","volume":"11","author":"AC Siepel","year":"1995","unstructured":"Siepel, A. C. et al. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res. Hum. Retroviruses 11(11), 1413\u20131416 (1995).","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"1","key":"22163_CR20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/nar\/gkg100","volume":"31","author":"SY Rhee","year":"2003","unstructured":"Rhee, S. Y. et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31(1), 298\u2013303 (2003).","journal-title":"Nucleic Acids Res."},{"issue":"Suppl 1","key":"22163_CR21","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1086\/505356","volume":"194","author":"RW Shafer","year":"2006","unstructured":"Shafer, R. W. Rationale and uses of a public HIV drug-resistance database. J. Infect. Dis. 194(Suppl 1), S51\u2013S58 (2006).","journal-title":"J. Infect. Dis."},{"key":"22163_CR22","unstructured":"LLC., T.S., StataCorp. Stata Statistical Software: Release 17. College Station. 2017."},{"issue":"1","key":"22163_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/QAI.0b013e318073c620","volume":"46","author":"LM Eyzaguirre","year":"2007","unstructured":"Eyzaguirre, L. M. et al. Genetic characterization of HIV-1 strains circulating in Kazakhstan. J. Acquir. Immune Defic. Syndr. 46(1), 19\u201323 (2007).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"22163_CR24","volume-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach 2nd edn. (World Health Organization, Geneva, 2016).","edition":"2"},{"issue":"5","key":"22163_CR25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1089\/aid.2006.22.470","volume":"22","author":"M Zarandia","year":"2006","unstructured":"Zarandia, M. et al. HIV-1 genetic diversity and genotypic drug susceptibility in the Republic of Georgia. AIDS Res. Hum. Retroviruses 22(5), 470\u2013476 (2006).","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"5","key":"22163_CR26","first-page":"570","volume":"39","author":"JK Carr","year":"2005","unstructured":"Carr, J. K. et al. Outbreak of a West African recombinant of HIV-1 in Tashkent, Uzbekistan. J. Acquir. Immune Defic. Syndr. 39(5), 570\u2013575 (2005).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"4","key":"22163_CR27","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1128\/AAC.01197-10","volume":"55","author":"AL McCormick","year":"2011","unstructured":"McCormick, A. L. et al. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. Antimicrob. Agents Chemother. 55(4), 1806\u20131809 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"22163_CR28","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/cid\/cir669","volume":"53","author":"AU Scherrer","year":"2011","unstructured":"Scherrer, A. U. et al. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin. Infect. Dis. 53(11), 1143\u20131152 (2011).","journal-title":"Clin. Infect. Dis."},{"issue":"50","key":"22163_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013555","volume":"97","author":"P Liu","year":"2018","unstructured":"Liu, P. et al. Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015. Medicine (Baltimore) 97(50), e13555 (2018).","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"22163_CR30","doi-asserted-by":"publisher","first-page":"20798","DOI":"10.7448\/IAS.19.1.20798","volume":"19","author":"K Brooks","year":"2016","unstructured":"Brooks, K. et al. Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya. J. Int. AIDS Soc. 19(1), 20798 (2016).","journal-title":"J. Int. AIDS Soc."},{"issue":"3","key":"22163_CR31","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1086\/649884","volume":"50","author":"MA Bender","year":"2010","unstructured":"Bender, M. A. et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin. Infect. Dis. 50(3), 416-425. (2010).","journal-title":"Clin. Infect. Dis."},{"issue":"17","key":"22163_CR32","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMp1710608","volume":"377","author":"C Beyrer","year":"2017","unstructured":"Beyrer, C. & Pozniak, A. HIV drug resistance\u2014An emerging threat to epidemic control. N. Engl. J. Med. 377(17), 1605\u20131607 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"22163_CR33","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMra025195","volume":"350","author":"F Clavel","year":"2004","unstructured":"Clavel, F. & Hance, A. J. HIV drug resistance. N. Engl. J. Med. 350(10), 1023\u20131035 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"22163_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.antiviral.2009.09.015","volume":"85","author":"R Paredes","year":"2010","unstructured":"Paredes, R. & Clotet, B. Clinical management of HIV-1 resistance. Antiviral Res. 85(1), 245\u2013265 (2010).","journal-title":"Antiviral Res."},{"issue":"11","key":"22163_CR35","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/cid\/cix1104","volume":"66","author":"N Yeganeh","year":"2018","unstructured":"Yeganeh, N. et al. Human immunodeficiency virus antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study. Clin. Infect. Dis. 66(11), 1770\u20131777 (2018).","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"22163_CR36","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S2352-3018(17)30190-X","volume":"5","author":"AN Phillips","year":"2018","unstructured":"Phillips, A. N. et al. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: A modelling study. Lancet HIV 5(3), e146\u2013e154 (2018).","journal-title":"Lancet HIV"},{"issue":"12","key":"22163_CR37","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1128\/AAC.39.12.2602","volume":"39","author":"SD Young","year":"1995","unstructured":"Young, S. D. et al. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39(12), 2602\u20132605 (1995).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"22163_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-199936010-00004","volume":"36","author":"MA Johnson","year":"1999","unstructured":"Johnson, M. A. et al. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36(1), 41\u201366 (1999).","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"22163_CR39","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","volume":"43","author":"BP Kearney","year":"2004","unstructured":"Kearney, B. P., Flaherty, J. F. & Shah, J. Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 43(9), 595\u2013612 (2004).","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"22163_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1517\/14656566.8.6.851","volume":"8","author":"SM Vrouenraets","year":"2007","unstructured":"Vrouenraets, S. M. et al. Efavirenz: A review. Expert Opin. Pharmacother. 8(6), 851\u2013871 (2007).","journal-title":"Expert Opin. Pharmacother."},{"issue":"5","key":"22163_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","volume":"11","author":"L Wittkop","year":"2011","unstructured":"Wittkop, L. et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect. Dis. 11(5), 363\u2013371 (2011).","journal-title":"Lancet Infect. Dis."},{"issue":"10","key":"22163_CR42","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1086\/644505","volume":"200","author":"J Vercauteren","year":"2009","unstructured":"Vercauteren, J. et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J. Infect. Dis. 200(10), 1503\u20131508 (2009).","journal-title":"J. Infect. Dis."},{"issue":"8","key":"22163_CR43","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/QAD.0b013e3283388742","volume":"24","author":"WH Wheeler","year":"2010","unstructured":"Wheeler, W. H. et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, US-2006. AIDS 24(8), 1203\u20131212 (2010).","journal-title":"AIDS"},{"issue":"9464","key":"22163_CR44","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0140-6736(05)71139-9","volume":"365","author":"M Markowitz","year":"2005","unstructured":"Markowitz, M. et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: A case report. Lancet 365(9464), 1031\u20131038 (2005).","journal-title":"Lancet"},{"issue":"3","key":"22163_CR45","first-page":"266","volume":"16","author":"MS Hirsch","year":"2008","unstructured":"Hirsch, M. S. et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med. 16(3), 266\u2013285 (2008).","journal-title":"Top HIV Med."},{"issue":"4","key":"22163_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","volume":"320","author":"MS Saag","year":"2018","unstructured":"Saag, M. S. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA 320(4), 379\u2013396 (2018).","journal-title":"JAMA"},{"issue":"1","key":"22163_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3851\/IMP2437","volume":"18","author":"KM Stadeli","year":"2013","unstructured":"Stadeli, K. M. & Richman, D. D. Rates of emergence of HIV drug resistance in resource-limited settings: A systematic review. Antivir. Ther. 18(1), 115\u2013123 (2013).","journal-title":"Antivir. Ther."},{"issue":"2","key":"22163_CR48","first-page":"67","volume":"10","author":"RW Shafer","year":"2008","unstructured":"Shafer, R. W. & Schapiro, J. M. HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev. 10(2), 67\u201384 (2008).","journal-title":"AIDS Rev."},{"issue":"4","key":"22163_CR49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/QAI.0b013e31817bbe93","volume":"48","author":"ES Svarovskaia","year":"2008","unstructured":"Svarovskaia, E. S. et al. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Defic. Syndr. 48(4), 428\u2013436 (2008).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"2","key":"22163_CR50","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1128\/jvi.70.2.1086-1090.1996","volume":"70","author":"AK Iversen","year":"1996","unstructured":"Iversen, A. K. et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70(2), 1086\u20131090 (1996).","journal-title":"J. Virol."},{"issue":"17","key":"22163_CR51","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/QAD.0000000000000485","volume":"28","author":"AN Kolomeets","year":"2014","unstructured":"Kolomeets, A. N. et al. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. AIDS 28(17), F1-8 (2014).","journal-title":"AIDS"},{"issue":"2","key":"22163_CR52","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2174\/187152611795589663","volume":"11","author":"JB Nachega","year":"2011","unstructured":"Nachega, J. B. et al. HIV treatment adherence, drug resistance, virologic failure: Evolving concepts. Infect. Disord. Drug Targets 11(2), 167\u2013174 (2011).","journal-title":"Infect. Disord. Drug Targets"},{"issue":"18","key":"22163_CR53","doi-asserted-by":"publisher","first-page":"8524","DOI":"10.1128\/JVI.74.18.8524-8531.2000","volume":"74","author":"F Mammano","year":"2000","unstructured":"Mammano, F. et al. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug. J. Virol. 74(18), 8524\u20138531 (2000).","journal-title":"J. Virol."},{"issue":"4","key":"22163_CR54","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jmb.2011.03.038","volume":"410","author":"MW Chang","year":"2011","unstructured":"Chang, M. W. & Torbett, B. E. Accessory mutations maintain stability in drug-resistant HIV-1 protease. J. Mol. Biol. 410(4), 756\u2013760 (2011).","journal-title":"J. Mol. Biol."},{"issue":"4","key":"22163_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231031","volume":"15","author":"AO Udeze","year":"2020","unstructured":"Udeze, A. O., Olaleye, D. O. & Odaibo, G. N. Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria. PLoS ONE 15(4), e0231031 (2020).","journal-title":"PLoS ONE"},{"issue":"10","key":"22163_CR56","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1097\/QAD.0000000000002234","volume":"33","author":"A Shroufi","year":"2019","unstructured":"Shroufi, A. et al. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: Predicted effect of using a single viral load to define efavirenz-based first-line failure. AIDS 33(10), 1635\u20131644 (2019).","journal-title":"AIDS"},{"key":"22163_CR57","unstructured":"WHO. Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, Guidelines Review Committee. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021 [cited 2022 July]. https:\/\/www.who.int\/publications\/i\/item\/9789240031593."},{"issue":"6","key":"22163_CR58","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/jac\/dkn127","volume":"61","author":"B Masquelier","year":"2008","unstructured":"Masquelier, B. et al. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir\/ritonavir. J. Antimicrob. Chemother. 61(6), 1362\u20131368 (2008).","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"22163_CR59","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/infdis\/jir505","volume":"204","author":"PE Sax","year":"2011","unstructured":"Sax, P. E. et al. Abacavir\/lamivudine versus tenofovir DF\/emtricitabine as part of combination regimens for initial treatment of HIV: Final results. J. Infect. Dis. 204(8), 1191\u20131201 (2011).","journal-title":"J. Infect. Dis."},{"key":"22163_CR60","unstructured":"Sanne, I., Shaw, A., Hinkle, J., Quinn, J., Moxham, C., Rousseau, F. Two randomized, controlled, equivalence trials of emtricitabine (FTC) to lamivudine (3TC). in XIV International AIDS Conference. 2002. Barcelona."},{"issue":"17","key":"22163_CR61","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1097\/00002030-200411190-00007","volume":"18","author":"CA Benson","year":"2004","unstructured":"Benson, C. A. et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS 18(17), 2269\u20132276 (2004).","journal-title":"AIDS"},{"issue":"2","key":"22163_CR62","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/aid.2012.0150","volume":"29","author":"E Martinez","year":"2013","unstructured":"Martinez, E. et al. Abacavir\/lamivudine versus tenofovir\/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS Res. Hum. Retroviruses 29(2), 235\u2013241 (2013).","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"1","key":"22163_CR63","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/cid\/ciu763","volume":"60","author":"C Rokx","year":"2015","unstructured":"Rokx, C. et al. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort. Clin. Infect. Dis. 60(1), 143\u2013153 (2015).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"22163_CR64","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/cid\/ciu767","volume":"60","author":"N Ford","year":"2015","unstructured":"Ford, N. et al. Editorial commentary: Comparative efficacy of lamivudine and emtricitabine: Comparing the results of randomized trials and cohorts. Clin. Infect. Dis. 60(1), 154\u2013156 (2015).","journal-title":"Clin. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22163-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22163-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22163-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T16:19:20Z","timestamp":1665677960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22163-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22163"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22163-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"11 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17195"}}